TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34978552
Drug: Lyophilized concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lyophilized concentrate of purple corn (Zea mays L.) 200 mg
Study: 36125974
Drug: Extracorporeal Shockwave
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shockwave Therapy (ESWT) + Stretching Exercises (SEs)
Study: 34267122
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTA) injection
Study: 33374687
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS) injection
Study: 33374687
Drug: Lidocaine (LD)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (LD) injection
Study: 33443879
Drug: Post-treatment nasofrontal
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment nasofrontal angle
Study: 33443879
Drug: Post-treatment nasolabial
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment nasolabial angle
Study: 33443879
Drug: Actual dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actual dosage
Study: 34371515
Drug: Continuous MMF
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous MMF treatment (control group)
Study: 33666188
Drug: Bepotastine 1.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepotastine 1.5% ophthalmic drops
Study: 33666188
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% ophthalmic drops
Study: 33549312
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (oral levofloxacin 500 mg and tinidazole 1,000 mg daily for 14 days)
Study: 33549312
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm (attempted pregnancy)
Study: 33549312
Drug: Treatment arm
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm (randomized subjects)
Study: 33639839
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg ABW
Study: 33639839
Drug: Sugammadex 2
Normalized name: sugammadex 200 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 2 mg/kg IBW
Study: 33639839
Drug: Neostigmine 5
Normalized name: neostigmine 5 mg/5 mL preservative-free intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 5 mg and glycopyrrolate 1 mg
Study: 33639839
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg/kg ABW
Study: 33639839
Drug: Sugammadex 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex 4 mg/kg IBW
Study: 33774169
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of acetaminophen orally every 6 hours for 1 day prior to and after surgery, then every 8 hours during postoperative days 2-5, with the option to take 5 mg of oxycodone every 6 hours as needed after surgery.
Study: 33774169
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oxycodone every 6 hours as needed and 1000 mg of acetaminophen orally every 6 hours as needed after surgery.
Study: 33774169
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oxycodone every 6 hours as needed without any additional acetaminophen after surgery.
Study: 34797431
Drug: Tapered implant
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tapered implant (TI)
Study: 34797431
Drug: Straight implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Straight implant (SI)
Study: 32741354
Drug: Weekly iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly iron and folate supplement for adolescent girls
Study: 32741354
Drug: Deworming programme
Normalized name: oxfendazole
DrugBank: Oxfendazole (DB11446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deworming programme twice per year
Study: 35325467
Drug: High-dose glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucocorticoid (10 mg/kg methylprednisolone)
Study: 35325467
Drug: Low-dose glucocorticoid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoid (8 mg dexamethasone)
Study: 32882163
Drug: Prasugrel 5
Normalized name: prasugrel 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 5 mg after 1 month of 10 mg prasugrel plus 100 mg aspirin daily (de-escalation group)
Study: 32882163
Drug: Prasugrel 10
Normalized name: prasugrel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 10 mg plus 100 mg aspirin daily (conventional group)
Study: 32882163
Drug: Prasugrel-based de-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel-based de-escalation therapy
Study: 33887247
Drug: Adjunctive host-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive host-directed therapies
Study: 32535263
Drug: Edaravone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (0.5 mg/kg intravenous after induction of anesthesia)
Study: 32881586
Drug: Endobronchial valve
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endobronchial valve treatment
Study: 35617211
Drug: Subtenon triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subtenon triamcinolone acetonide (TAAC) injection (4mg) with MMC‐TRAB
Study: 36458119
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual + aerobic exercise training (40-min twice a week for 8 weeks)
Study: 36458119
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual + aerobic exercise training
Study: 32576199
Drug: ENG-releasing subdermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENG-releasing subdermal contraceptive implant
Study: 32451288
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) plus pharmacotherapy on demand
Study: 32978352
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine solution
Study: 34998000
Drug: Intralesional MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional MMR injections
Study: 34998000
Drug: Intralesional BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional BCG injection
Study: 34998000
Drug: Intralesional candida
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional candida antigen injection
Study: 34033939
Drug: scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: scaling and root planing with indocyanine green-based antimicrobial photodynamic therapy (perio-green, 0.1 mg/ml)
Study: 34033939
Drug: scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: scaling and root planing with indocyanine green-based antimicrobial photodynamic therapy
Study: 34464752
Drug: Multimodal prehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal prehabilitation combining a mixed-nutrient supplement with structured supervised and home-based exercise training, and relaxation strategies (Prehab)
Study: 32338106
Drug: Low-dose SPN-810
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SPN-810 (12/18 mg/day)
Study: 32338106
Drug: Medium-dose SPN-810
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose SPN-810 (24/36 mg/day)
Study: 32338106
Drug: High-dose SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SPN-810 (36/54 mg/day)
Study: 33185468
Drug: 6.25 mg
Normalized name: captopril 6.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.25 mg SHP465 mixed amphetamine salts (MAS) once daily
Study: 32902413
Drug: Baricitinib (JAK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib (JAK inhibitor)
Study: 32142492
Drug: Hydromorphone 0.05
Normalized name: HYDROMORPHONE 0.05MG/BUPIVACAINE 0.1%/ML/NS INJ,BAG,200ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.05 mg/mL + nalbuphine 0.5 mg/mL (group LN)
Study: 32142492
Drug: Hydromorphone 0.05
Normalized name: HYDROMORPHONE 0.05MG/BUPIVACAINE 0.1%/ML/NS INJ,BAG,200ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.05 mg/mL + nalbuphine 0.7 mg/mL (group MN)
Study: 32142492
Drug: Hydromorphone 0.05
Normalized name: HYDROMORPHONE 0.05MG/BUPIVACAINE 0.1%/ML/NS INJ,BAG,200ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydromorphone 0.05 mg/mL + nalbuphine 0.9 mg/mL (group HN)
Study: 34695525
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg twice daily
Study: 32321518
Drug: Once-daily indacaterol/glycopyrronium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily indacaterol/glycopyrronium (IND/GLY) 110/50 μg
Study: 32321518
Drug: Twice-daily salmeterol/fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily salmeterol/fluticasone (SFC) 50/500 μg
Study: 38880172
Drug: Systemic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic adjuvant therapy
Study: 33139143
Drug: Multifaceted stewardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted stewardship intervention including education on guideline-based treatment, tests of antimicrobial treatment, implementation of a clinical treatment algorithm, and audit and feedback.
Study: 32717068
Drug: Oral bisphosphonates
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral bisphosphonates (oBP)
Study: 33167078
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A absorption (retinyl palmitate) after soymilk consumption (501 IU vitamin A)
Study: 33167078
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 absorption after soymilk consumption (119 IU vitamin D2)
Study: 32586394
Drug: High-Dose LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose LMWH (Enoxaparin 70 IU/kg twice daily)
Study: 32586394
Drug: Low-Dose LMWH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose LMWH (Enoxaparin 4000 IU once daily)
Study: 32586394
Drug: High-Dose LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose LMWH
Study: 32586394
Drug: Low-Dose LMWH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-Dose LMWH
Study: 35421217
Drug: Integrated agricultural
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated agricultural intervention including distribution of micronutrient powders (MNP), poultry, seeds of greens and onions, soap and chlorine solution, and monthly behavior change trainings.
Study: 33914660
Drug: ANS +
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ANS + CARN (20 mg/kg body weight)
Study: 32013882
Drug: Pb1 (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pb1 (2000 mg/kg Pb (NO3)2)
Study: 32013882
Drug: Pb2 (10,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pb2 (10,000 mg/kg Pb (NO3)2)
Study: 35971859
Drug: Family-based behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioural obesity treatment (FBT)
Study: 33571040
Drug: Sambucus ebulus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sambucus ebulus L.
Study: 34997178
Drug: 300 mg/day
Normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/day ALA
Study: 33053078
Drug: 1.2g of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2g of ginger daily for 90 days
Study: 33053078
Drug: 1.2g of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2g of placebo daily for 90 days
Study: 38940494
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants
Study: 34129960
Drug: Antimalarial drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial drugs (quinine, artemisinin combination therapies, and multiple drug combinations)
Study: 34129960
Drug: Artemisinin combination
Normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin combination therapies
Study: 34129960
Drug: Multiple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple drug combinations
Study: 34129960
Drug: Randomized trials
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized trials evaluating drug safety
Study: 36465660
Drug: Dim Red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim Red Light + Placebo Capsules
Study: 34310730
Drug: No EPO
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No EPO treatment
Study: 36394750
Drug: polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: polyethylene glycol loxenatide injection + metformin
Study: 34175572
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (provided balanced information about ethical dilemmas)
Study: 33203625
Drug: PQT (esomeprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: PQT (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, polaprezinc 75 mg)
Study: 33203625
Drug: Bismuth-containing quadruple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-containing quadruple therapy (esomeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, bismuth potassium citrate 220 mg)
Study: 34882169
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of armodafinil
Study: 34882169
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg of armodafinil
Study: 32444553
Drug: Multimodal lifestyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal lifestyle intervention (INT) including bright light therapy (BLT), physical activity (PA), and sleep hygiene education
Study: 32488989
Drug: Sapanisertib 30
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib 30 mg once weekly
Study: 36146944
Drug: Sapanisertib 4
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sapanisertib 4 mg plus TAK-117 200 mg, both once daily for 3 days/week
Study: 35813435
Drug: Sandplay therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandplay therapy (8 individual box court game tutoring sessions, once a week)
Study: 34378869
Drug: Sandplay therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandplay therapy
Study: 616743266
Drug: Being on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Being on antiretroviral therapy at first antenatal care booking
Study: 32801342
Drug: l-DOPA 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-DOPA 100/25 mg
Study: 32801342
Drug: l-DOPA 200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-DOPA 200/50 mg
Study: 32481262
Drug: Successful clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful clinical outcome (SCO) defined as significant improvement in 2 of 3 of L-vas, R-vas, or ODI score at follow-up
Study: 35922251
Drug: Cemiplimab (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemiplimab (350 mg intravenously every 3 weeks)
Study: 38959480
Drug: Chemotherapy (investigator's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (investigator's choice)
Study: 32542515
Drug: Neuronavigated rTMS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuronavigated rTMS (10 Hz, 90% of resting motor threshold, 1,600 pulses over 20 min twice per day) for five days
Study: 36721157
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (Control)
Study: 33528092
Drug: Topical acidified
Normalized name: Acidifiers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical acidified aliphatic ester
Study: 35882474
Drug: HFL treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFL treatment
Study: 35882474
Drug: Dual, HFL,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual, HFL, and RF treatments
Study: 32276098
Drug: PALO 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALO 0.25 mg IV infusion (30-minute infusion)
Study: 32276098
Drug: PALO 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: PALO 0.25 mg IV bolus (30-second bolus)
Study: 32420357
Drug: KIR3DL1-HLA-Bw4 combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: KIR3DL1-HLA-Bw4 combination
Study: 34552329
Drug: OMACOR (OM3EE)
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMACOR (OM3EE) 2 g/day for 4 weeks, then 4 g/day for 8 weeks
Study: 34164754
Drug: Surgical drill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical drill guide with implant insertion guide (SDIG)
Study: 34455631
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of β‐NAG2 lotion for 8 weeks
Study: 32689617
Drug: Combination (joint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (joint mobilization and active stretching)
Study: 36501060
Drug: p-synephrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (3 mg/kg)
Study: 36501060
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg/kg cellulose)
Study: 32141627
Drug: Statin use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin use (dose intensity analysis) 6 months post-diagnosis
Study: 36368598
Drug: Reduction in
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction in deep subcutaneous adipose tissue (dSAT)
Study: 32577886
Drug: Vitamin B
Normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B complex supplements
Study: 35405933
Drug: 5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g/kg body mass (BM)/d
Study: 35405933
Drug: 7 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/kg body mass (BM)/d
Study: 35405933
Drug: 10 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g/kg body mass (BM)/d
Study: 32227756
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy (coronary angiography and revascularization if appropriate added to medical therapy)
Study: 32227756
Drug: Conservative strategy
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative strategy (medical therapy alone, angiography reserved for those in whom medical therapy had failed)
Study: 33357682
Drug: 1,000 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/kg benzoic acid (BA1)
Study: 33357682
Drug: 2,000 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 mg/kg benzoic acid (BA2)
Study: 34634640
Drug: Intranasal naloxone
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal naloxone
Study: 35667730
Drug: Postoperative lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative lidocaine infusion at 1.33 mg/kg/hour
Study: 35583280
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous vitamin C
Study: 35660372
Drug: Electroacupuncture (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (twice a week for 30 min for 8 weeks)
Study: 33826158
Drug: Center-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Center-based exercise training (ET) within a cardiac rehabilitation (CR) program; specific dosage and duration not mentioned.
Study: 32078090
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 200 mL of still mineral water
Study: 32078090
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 400 mL of still mineral water
Study: 32078090
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 600 mL of still mineral water
Study: 32078090
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 800 mL of still mineral water
Study: 32078090
Drug: All volumes
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All volumes of water greater than 200 mL
Study: 36079790
Drug: EAA+ (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: EAA+ (9 g EAAs, 3 g leucine)
Study: 36079790
Drug: BCAAs (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAAs (6 g BCAAs, 3 g leucine)
Study: 33638810
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (≥ 3 years and 2 years)
Study: 39135126
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day)
Study: 34585700
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of PEITC-rich vegetable sauce
Study: 34585700
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of PEITC-rich vegetable sauce
Study: 34585700
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of placebo sauce
Study: 36458325
Drug: Vonoprazan 20
Normalized name: vonoprazan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 10 days (V10)